The uptake of the hip fracture core outcome set:analysis of 20 years of hip fracture trials by Smith, Toby O et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1093/ageing/afz018
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Smith, T. O., Collier, T., Sheehan, K. J., & Sherrington, C. (2019). The uptake of the hip fracture core outcome
set: analysis of 20 years of hip fracture trials. Age and Ageing, 48(4), 595-598. [afz018].
https://doi.org/10.1093/ageing/afz018
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
For Review Only
The uptake of the hip fracture core outcome set: analysis of 
20 years of hip fracture trials  
Journal: Age and Ageing
Manuscript ID AA-18-0924.R2
Manuscript Category: Short Report
Keywords: Hip Fracture, Trials, Research, Outcomes
Keypoints:
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set has limited uptake across all five recommended domains since its 
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researchers are not using this core outcome set for future trials
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ABSTRACT
BACKGROUND: Clinical trials test the effectiveness or efficacy of treatments. It is important that 
researchers evaluate interventions with the most meaningful outcome measures. The 2014 hip 
fracture core outcome set recommended that mortality, mobility, pain, activities of daily living and 
health related-quality of life (HRQOL) should be assessed in all trials of patient with hip fracture. The 
purpose of this analysis was to determine the uptake of these recommendation. 
METHODS: All trials registered from 1997 to 2018 recruiting participants following hip fracture were 
identified from the ClinicalTrials.gov trials registry. The frequency of each core domain adopted 
annually were assessed.
RESULTS: 311 trials were identified and analysed. On analysing trial registries for years which 
presented a minimum of 10 registrations, full core outcome set adoption ranged from 0% (2017; 2018) 
to 24% (2009). Mortality and mobility were the most consistently reported domains (mortality: 27% 
(2017) to 56% (2011); mobility: 36% (2015) to 60% (2004)). In contrast, pain and HRQOL were least 
reported (pain: 14% (2017) to 61% (2015); HRQOL: 10% (2010) to 11% (2008)). There was no clear 
change in core outcome domain set adoption following the publication of Hayward et al’s (2014) core 
outcome set.  
CONCLUSIONS: There has been limited adoption of the hip fracture core outcome set from its 
publication in 2014. Further consideration to improve implementation is required to improved uptake.
Keywords: Hip fracture; trials; research; outcomes
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Key points:
 Researchers should base their choice of outcome measures on core outcome set 
recommendations.
 The current hip fracture core outcome set has limited uptake across all five recommended 
domains since its 2014 publication.
 Further investigation is required to determine why researchers are not using this core 
outcome set when designing hip fracture trials. 
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INTRODUCTION
Clinical trials determine whether an intervention is effective for patients by comparing their effects 
on outcome measures chosen to identify benefit or harm relative to usual care or a different 
intervention [1]. The reported effects on outcome measures are used to make decisions on whether 
treatments are recommended for clinical practice. It is therefore essential that outcome measures 
reported in trials are important for patients, clinicians and wider decision-makers. 
A core outcome set is an agreed recommended list of domains which researchers should assess, and 
includes a consensus on measures to be used [2]. It consists of ‘domains’ and ‘instruments’. A domain 
is a specific ‘area’ which should be measured i.e. quality of life, healthcare costs, body function, 
biomarkers. An instrument is the outcome measure which measures that specific domain i.e. 
questionnaires to assess quality of life, scales to assess cost, measures of body function, and tests and 
imaging to assess biomarkers. By following a core outcome set, researchers are better informed in 
their selection of outcome measures. There is also reduced risk of inconsistent reporting in outcome 
measures which can be a barrier to evidence synthesis [4]. 
Core outcome sets are most frequently developed through a process including: (1) literature reviews 
to identified relevant domains; (2) qualitative research to gain views from patients, clinicians and 
other stakeholders on important domains; and (3) agreement on domain selection through Delphi 
exercises and consensus meetings [3]. Once domains have been identified, instruments to measure 
these domains are determined through literature reviews, before the potential instruments are 
analysed for their clinimetric properties to establish the best instruments available to measure each 
domain [3]. 
Hayward et al [5] were the first to report a core outcome set for all hip fracture trials. They identified 
five domains following a series of consensus meetings across stakeholder groups. These were 
mortality, pain, activities of daily living, mobility, and health-related quality of life (HRQOL) [5]. It is 
not known whether the publication of this core outcome set led to changes in selection of outcome 
measures in hip fracture trials. Therefore, this study aims to: 1) analyse the temporal trends in 
outcome measure selection in hip fracture trials; and 2) determine whether outcome measure 
selection changed with the publication of the core outcome set for hip fracture trials. 
METHODS
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We adopted Kirkham et al’s [6] approach to core outcome set assessment using a trial registration 
database. This is an efficient means of estimating uptake compared to published trial reports [6,7]. 
We searched the trial registry ClinicalTrials.gov to identify all trials registered from 1st January 1997 to 
1st May 2018, recruiting people with hip fracture. The following filters were applied to identify eligible 
trials: “conditions: hip fracture”. No restriction was placed on the type of study or the phase of trial. 
From all eligible trial registrations, data were extracted for each component of the core outcome set 
for hip fracture trials [5]. These were: mortality; pain; activity of daily living; mobility and HRQOL. If a 
trial had registered a composite outcome, we considered all individual outcomes in the composite. 
Data extraction also included: year of registration, country of origin, sample size, age of participants 
recruited; funding source (industry vs. research council vs. mixed), study design (randomised 
controlled trial (RCT) vs. non-RCT), duration of follow-up, whether participants with cognitive 
impairment were eligible for trial enrolment, the intervention type under investigation (drug or non-
drug trial/surgical or non-surgical) and phase of trial.
All trial registry entries were reviewed and extracted by one reviewer (TS). An independent reviewer 
(TC) reviewed a random sample of 30% (n=93) of the data collected to ensure data extraction accuracy. 
Disagreements in data extracted were resolved through discussion. Where available, full-text 
protocols, trial publications, or study reports were reviewed to verify data (n=83). These were 
identified through the MEDLINE and EMBASE databases via the Ovid Platform. When data differed 
(n=6), the data from the final report was included in the data extraction table. For trial registry entries 
where a publication could not be identified (n=228), the corresponding researcher named on the trial 
registry was emailed and asked to verify the core outcome set data. 
Data Analysis
We reported the frequency of registered hip fracture trials which reported each component of the 
core outcome set. These were assessed from 1997 to 2018. We also assessed whether the frequency 
of core outcome set adoption changed after the publication of the 2014 Hip Fracture core outcome 
set [5]. Analyses were made assessing each year where a minimum of 10 trials were registered. 
RESULTS
Characteristics of trial registrations
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In total, 311 trial registries were identified (Supplementary Figure 1). The characteristics of these are 
presented in Supplementary Table 1 and Supplementary Table 2. In total, 43% of trials were 
registered in Europe, 24% in Asia and 31% in North America. Trials had a mean sample size of 196 
participants (Standard Deviation (SD): 299) and mean trial duration of 9.4 months (SD: 17.2). Fifty-five 
percent of trials excluded participants with cognitive impairment.
Uptake of core outcome set
Table 1 illustrates the distribution of core outcome set adoption from 1997 to 2018. Full core outcome 
set adoption ranged annually from 0% (Years 1997-1999,2001,2003,2005,2006,2007,2018) to 100% 
(Year 2000). On analysing trial registries for years which presented a minimum of 10 registrations, full 
core outcome set adoption ranged from 0% (2017; 2018) to 24% (2009) (Figure 1). Mortality and 
mobility were consistently the most reported domains. Mortality ranged from 27% (2017) to 56% 
(2011), whilst mobility ranged from 36% (2015) to 60% (2004). In contrast, pain and HRQOL were the 
least reported domains. Pain was reported in 14% (2017) to 61% (2015) of trial registries per year, 
whilst HRQOL was reported in 10% (2010) to 11% (2008) per year. There was no clear change in core 
outcome set domain adoption following the publication of Hayward et al’s [5] core outcome set.  
DISCUSSION
This analysis indicates infrequent use of the full core outcome set for hip fracture trials. None of the 
five domains are consistently reported before or after the core outcome sets publication [5] 
It is not clear whether the hip fracture core outcome set is not considered fit for purpose during trial 
development, or whether it is fit for purpose but not being adopted. For the former, the limited 
stakeholder involvement in the development of the hip fracture core outcome set may undermine its 
fitness for purpose [5]. Indeed, Tunis et al [10] and organisations developing core outcome sets (e.g. 
COMET and OMERACT) recommend a strategy to improve stakeholder engagement (patients, 
clinicians, industry and regulatory authorities) during development. For the latter, promotion of the 
core outcome set may be required. Through wider awareness of its existence, the applicability of the 
core outcome set to a breath of trials may be explored. For example, the core outcome set may be 
more applicable to surgical compared to anaesthetic or rehabilitation trials. Further consultation with 
increased engagement of the wider research community may therefore be an important step to 
address the reported limited uptake.
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Mortality was the most frequently consistent domain reported. This however remained low, ranging 
from 27% (2017) to 56% (2011) when 10 or more registries were published in a given year. Given that 
trials should report adverse events in accordance with Good Clinical Practice [11], the collection of 
this data should be mandatory. This may be attributed to either trials not collecting this data or 
researchers considering this a regulatory requirement and not a specific outcome measure. Clear 
reporting of trial protocols and methodologies is a cornerstone to the SPIRIT [12] and CONSORT [13] 
recommendations. Promotion of the core outcome set with clear reporting of the outcome measures 
is paramount. 
Haywood et al [5] did not recommend instruments for measuring the domains identified in the core 
outcome set. Such guidance should only be made once the validity and reliability of outcome measures 
for a specific domain have been evaluated.  When used in combination with agreed trials end points, 
as being developed in perioperative trials through the Standardized Endpoints in Perioperative 
Medicine (StEP) initiative, researchers will have clearer guidance on what measures to use and when. 
This will improve outcomes reporting consistency across trials enabling meta-analyses and clinical 
guideline formation [14]. 
We limited our search to ClinicalTrials.gov which may have led to the exclusion of trials indexed in 
other registries. Further, we did determine the proportion of published trials which adopted the core 
outcome set. We believe trials identified in this paper are likely to be a representative sample as all 
registries endorsed by the International Committee of Medical Journal Editors must meet common 
standards, and most journals require trial registration for publication.  
CONCLUSIONS
The choice of which outcome measures to use in trials of interventions for hip fracture has not 
changed following the publication of the 2014 core outcome set. There is limited uptake of the core 
outcome set.  There is a need to determine why uptake is poor. Further consideration of dissemination 
and wider stakeholder involvement may be warranted.
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FIGURE AND TABLE LEGENDS
Figure 1: Graph of uptake of core domain for the hip fracture core outcome set from 2004 to 2018 
(where 10 or more registrations were recorded per year).
Table 1: Frequency (%) of domains reported and complete adoption of the core outcome set in 
included trial registrations by year. 
Supplementary Table 1: Characteristics of included trials registered on ClinicalTrials.gov
Supplementary Table 2: Country of origin for registered trial protocols
Supplementary Figure 1: Flow-chart of identification of trial registrations from ClinicalTrial.gov 
database
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Table 1: Frequency (%) of domains reported and complete adoption of the core outcome set in included trial registrations by year. 
Domain Total 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
N 311 0 1 1 1 1 7 4 10 9 7 12
Mortality 146 (46.9) 0 (0.0) 1 (100) 0 (0.0) 1 (100) 1 (100) 4 (57.1) 2 (50.0) 5 (50.0) 8 (88.9) 2 (28.6) 6 (50.0)
Pain 127 (40.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 3 (42.9) 1 (25.0) 2 (20.0) 2 (22.2) 2 (28.6) 2 (16.7)
ADL 116 (37.3) 0 (0.0) 1 (100) 1 (100) 1 (100) 1 (100) 2 (28.6) 1 (25.0) 5 (50.0) 5 (55.6) 2 (28.6) 4 (33.3)
Mobility 143 (46.0) 0 (0.0) 1 (100) 1 (100) 1 (100) 0 (0.0) 3 (42.9) 1 (25.0) 6 (60.0) 4 (44.4) 2 (28.6) 7 (58.3)
HRQOL 91 (29.3) 0 (0.0) 1 (100) 1 (100) 1 (100) 1 (100) 3 (42.9) 0 (0.0) 3 (30.0) 3 (33.3) 2 (28.6) 2 (16.7)
All COS 37 (11.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 2 (28.6) 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 2 (16.7)
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
N 19 21 25 16 23 21 28 36 23 22 15
Mortality 8 (42.1) 14 (66.7) 13 (52.0) 9 (56.3) 10 (43.5) 9 (42.9) 12 (42.9) 11 (30.6) 12 (52.2) 6 (27.3) 10 (66.7)
Pain 8 (42.1) 12 (57.1) 10 (40.0) 6 (37.5) 10 (43.5) 11 (52.4) 13 (46.4) 22 (61.1) 12 (52.2) 3 (13.6) 4 (26.7)
ADL 6 (31.6) 9 (42.9) 11 (44.0) 6 (37.5) 6 (26.1) 8 (38.1) 12 (42.9) 8 (22.2) 10 (43.5) 7 (31.8) 6 (40.0)
Mobility 9 (47.4) 11 (52.4) 11 (44.0) 7 (43.8) 10 (43.5) 10 (47.6) 15 (53.6) 13 (36.1) 13 (56.5) 8 (36.4) 7 (46.7)
HRQOL 2 (10.5) 7 (33.3) 10 (40.0) 4 (25.0) 7 (30.4) 7 (33.3) 11 (39.3) 5 (13.9) 8 (34.8) 8 (36.4) 3 (20.0)
All COS 1 (5.3) 5 (23.8) 3 (12.0) 2 (12.5) 5 (21.7) 3 (14.3) 4 (14.3) 2 (5.6) 5 (21.7) 0 (0.0) 0 (0.0)
ADL – activities of daily living; COS – core outcome set; HRQOL – health-related quality of life; N – number of trial registrations
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ABSTRACT
BACKGROUND: Clinical trials test the effectiveness or efficacy of treatments. It is important that 
researchers evaluate interventions with the most meaningful outcome measures. The 2014 hip 
fracture core outcome set recommended that mortality, mobility, pain, activities of daily living and 
health related-quality of life (HRQOL) should be assessed in all trials of patient with hip fracture. The 
purpose of this analysis was to determine the uptake of these recommendation. 
METHODS: All trials registered from 1997 to 2018 recruiting participants following hip fracture were 
identified from the ClinicalTrials.gov trials registry. The frequency of each core domain adopted 
annually were assessed.
RESULTS: 311 trials were identified and analysed. On analysing trial registries for years which 
presented a minimum of 10 registrations, full core outcome set adoption ranged from 0% (2017; 2018) 
to 24% (2009). Mortality and mobility were the most consistently reported domains (mortality: 27% 
(2017) to 56% (2011); mobility: 36% (2015) to 60% (2004)). In contrast, pain and HRQOL were least 
reported (pain: 14% (2017) to 61% (2015); HRQOL: 10% (2010) to 11% (2008)). There was no clear 
change in core outcome domain set adoption following the publication of Hayward et al’s (2014) core 
outcome set.  
CONCLUSIONS: There has been limited adoption of the hip fracture core outcome set from its 
publication in 2014. Further consideration to improve implementation is required to improved uptake.
Keywords: Hip fracture; trials; research; outcomes
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Key points:
 Researchers should base their choice of outcome measures on core outcome set 
recommendations.
 The current hip fracture core outcome set has limited uptake across all five recommended 
domains since its 2014 publication.
 Further investigation is required to determine why researchers are not using this core 
outcome set when designing hip fracture trials. 
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INTRODUCTION
Clinical trials determine whether an intervention is effective for patients by comparing their effects 
on outcome measures chosen to identify benefit or harm relative to usual care or a different 
intervention [1]. The reported effects on outcome measures are used to make decisions on whether 
treatments are recommended for clinical practice. It is therefore essential that outcome measures 
reported in trials are important for patients, clinicians and wider decision-makers. 
A core outcome set is an agreed recommended list of domains which researchers should assess, and 
includes a consensus on measures to be used [2]. It consists of ‘domains’ and ‘instruments’. A domain 
is a specific ‘area’ which should be measured i.e. quality of life, healthcare costs, body function, 
biomarkers. An instrument is the outcome measure which measures that specific domain i.e. 
questionnaires to assess quality of life, scales to assess cost, measures of body function, and tests and 
imaging to assess biomarkers. By following a core outcome set, researchers are better informed in 
their selection of outcome measures. There is also reduced risk of inconsistent reporting in outcome 
measures which can be a barrier to evidence synthesis [4]. 
Core outcome sets are most frequently developed through a process including: (1) literature reviews 
to identified relevant domains; (2) qualitative research to gain views from patients, clinicians and 
other stakeholders on important domains; and (3) agreement on domain selection through Delphi 
exercises and consensus meetings [3]. Once domains have been identified, instruments to measure 
these domains are determined through literature reviews, before the potential instruments are 
analysed for their clinimetric properties to establish the best instruments available to measure each 
domain [3]. 
Hayward et al [5] were the first to report a core outcome set for all hip fracture trials. They identified 
five domains following a series of consensus meetings across stakeholder groups. These were 
mortality, pain, activities of daily living, mobility, and health-related quality of life (HRQOL) [5]. It is 
not known whether the publication of this core outcome set led to changes in selection of outcome 
measures in hip fracture trials. Therefore, this study aims to: 1) analyse the temporal trends in 
outcome measure selection in hip fracture trials; and 2) determine whether outcome measure 
selection changed with the publication of the core outcome set for hip fracture trials. 
METHODS
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We adopted Kirkham et al’s [6] approach to core outcome set assessment using a trial registration 
database. This is an efficient means of estimating uptake compared to published trial reports [6,7]. 
We searched the trial registry ClinicalTrials.gov to identify all trials registered from 1st January 1997 to 
1st May 2018, recruiting people with hip fracture. The following filters were applied to identify eligible 
trials: “conditions: hip fracture”. No restriction was placed on the type of study or the phase of trial. 
From all eligible trial registrations, data were extracted for each component of the core outcome set 
for hip fracture trials [5]. These were: mortality; pain; activity of daily living; mobility and HRQOL. If a 
trial had registered a composite outcome, we considered all individual outcomes in the composite. 
Data extraction also included: year of registration, country of origin, sample size, age of participants 
recruited; funding source (industry vs. research council vs. mixed), study design (randomised 
controlled trial (RCT) vs. non-RCT), duration of follow-up, whether participants with cognitive 
impairment were eligible for trial enrolment, the intervention type under investigation (drug or non-
drug trial/surgical or non-surgical) and phase of trial.
All trial registry entries were reviewed and extracted by one reviewer (TS). An independent reviewer 
(TC) reviewed a random sample of 30% (n=93) of the data collected to ensure data extraction accuracy. 
Disagreements in data extracted were resolved through discussion. Where available, full-text 
protocols, trial publications, or study reports were reviewed to verify data (n=83). These were 
identified through the MEDLINE and EMBASE databases via the Ovid Platform. When data differed 
(n=6), the data from the final report was included in the data extraction table. For trial registry entries 
where a publication could not be identified (n=228), the corresponding researcher named on the trial 
registry was emailed and asked to verify the core outcome set data. 
Data Analysis
We reported the frequency of registered hip fracture trials which reported each component of the 
core outcome set. These were assessed from 1997 to 2018. We also assessed whether the frequency 
of core outcome set adoption changed after the publication of the 2014 Hip Fracture core outcome 
set [5]. Analyses were made assessing each year where a minimum of 10 trials were registered. 
RESULTS
Characteristics of trial registrations
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In total, 311 trial registries were identified (Supplementary Figure 1). The characteristics of these are 
presented in Supplementary Table 1 and Supplementary Table 2. In total, 43% of trials were 
registered in Europe, 24% in Asia and 31% in North America. Trials had a mean sample size of 196 
participants (Standard Deviation (SD): 299) and mean trial duration of 9.4 months (SD: 17.2). Fifty-five 
percent of trials excluded participants with cognitive impairment.
Uptake of core outcome set
Table 1 illustrates the distribution of core outcome set adoption from 1997 to 2018. Full core outcome 
set adoption ranged annually from 0% (Years 1997-1999,2001,2003,2005,2006,2007,2018) to 100% 
(Year 2000). On analysing trial registries for years which presented a minimum of 10 registrations, full 
core outcome set adoption ranged from 0% (2017; 2018) to 24% (2009) (Figure 1). Mortality and 
mobility were consistently the most reported domains. Mortality ranged from 27% (2017) to 56% 
(2011), whilst mobility ranged from 36% (2015) to 60% (2004). In contrast, pain and HRQOL were the 
least reported domains. Pain was reported in 14% (2017) to 61% (2015) of trial registries per year, 
whilst HRQOL was reported in 10% (2010) to 11% (2008) per year. There was no clear change in core 
outcome set domain adoption following the publication of Hayward et al’s [5] core outcome set.  
DISCUSSION
This analysis indicates infrequent use of the full core outcome set for hip fracture trials. None of the 
five domains are consistently reported before or after the core outcome sets publication [5] 
It is not clear whether the hip fracture core outcome set is not considered fit for purpose during trial 
development, or whether it is fit for purpose but not being adopted. For the former, the limited 
stakeholder involvement in the development of the hip fracture core outcome set may undermine its 
fitness for purpose [5]. Indeed, Tunis et al [10] and organisations developing core outcome sets (e.g. 
COMET and OMERACT) recommend a strategy to improve stakeholder engagement (patients, 
clinicians, industry and regulatory authorities) during development. For the latter, promotion of the 
core outcome set may be required. Through wider awareness of its existence, the applicability of the 
core outcome set to a breath of trials may be explored. For example, the core outcome set may be 
more applicable to surgical compared to anaesthetic or rehabilitation trials. Further consultation with 
increased engagement of the wider research community may therefore be an important step to 
address the reported limited uptake.
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Mortality was the most frequently consistent domain reported. This however remained low, ranging 
from 27% (2017) to 56% (2011) when 10 or more registries were published in a given year. Given that 
trials should report adverse events in accordance with Good Clinical Practice [11], the collection of 
this data should be mandatory. This may be attributed to either trials not collecting this data or 
researchers considering this a regulatory requirement and not a specific outcome measure. Clear 
reporting of trial protocols and methodologies is a cornerstone to the SPIRIT [12] and CONSORT [13] 
recommendations. Promotion of the core outcome set with clear reporting of the outcome measures 
is paramount. 
Haywood et al [5] did not recommend instruments for measuring the domains identified in the core 
outcome set. Such guidance should only be made once the validity and reliability of outcome measures 
for a specific domain have been evaluated.  When used in combination with agreed trials end points, 
as being developed in perioperative trials through the Standardized Endpoints in Perioperative 
Medicine (StEP) initiative, researchers will have clearer guidance on what measures to use and when. 
This will improve outcomes reporting consistency across trials enabling meta-analyses and clinical 
guideline formation [14]. 
We limited our search to ClinicalTrials.gov which may have led to the exclusion of trials indexed in 
other registries. We believe trials identified in this paper are likely to be a representative sample as all 
registries endorsed by the International Committee of Medical Journal Editors must meet common 
standards, and most journals require trial registration for publication.  
CONCLUSIONS
The choice of which outcome measures to use in trials of interventions for hip fracture has not 
changed following the publication of the 2014 core outcome set. There is limited uptake of the core 
outcome set.  There is a need to determine why uptake is poor. Further consideration of dissemination 
and wider stakeholder involvement may be warranted.
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FIGURE AND TABLE LEGENDS
Figure 1: Graph of uptake of core domain for the hip fracture core outcome set from 2004 to 2018 
(where 10 or more registrations were recorded per year).
Table 1: Frequency (%) of domains reported and complete adoption of the core outcome set in 
included trial registrations by year. 
Supplementary Table 1: Characteristics of included trials registered on ClinicalTrials.gov
Supplementary Table 2: Country of origin for registered trial protocols
Supplementary Figure 1: Flow-chart of identification of trial registrations from ClinicalTrial.gov 
database
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Table 1: Frequency (%) of domains reported and complete adoption of the core outcome set in included trial registrations by year. 
Domain Total 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
N 311 0 1 1 1 1 7 4 10 9 7 12
Mortality 146 (46.9) 0 (0.0) 1 (100) 0 (0.0) 1 (100) 1 (100) 4 (57.1) 2 (50.0) 5 (50.0) 8 (88.9) 2 (28.6) 6 (50.0)
Pain 127 (40.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 3 (42.9) 1 (25.0) 2 (20.0) 2 (22.2) 2 (28.6) 2 (16.7)
ADL 116 (37.3) 0 (0.0) 1 (100) 1 (100) 1 (100) 1 (100) 2 (28.6) 1 (25.0) 5 (50.0) 5 (55.6) 2 (28.6) 4 (33.3)
Mobility 143 (46.0) 0 (0.0) 1 (100) 1 (100) 1 (100) 0 (0.0) 3 (42.9) 1 (25.0) 6 (60.0) 4 (44.4) 2 (28.6) 7 (58.3)
HRQOL 91 (29.3) 0 (0.0) 1 (100) 1 (100) 1 (100) 1 (100) 3 (42.9) 0 (0.0) 3 (30.0) 3 (33.3) 2 (28.6) 2 (16.7)
All COS 37 (11.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 2 (28.6) 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 2 (16.7)
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
N 19 21 25 16 23 21 28 36 23 22 15
Mortality 8 (42.1) 14 (66.7) 13 (52.0) 9 (56.3) 10 (43.5) 9 (42.9) 12 (42.9) 11 (30.6) 12 (52.2) 6 (27.3) 10 (66.7)
Pain 8 (42.1) 12 (57.1) 10 (40.0) 6 (37.5) 10 (43.5) 11 (52.4) 13 (46.4) 22 (61.1) 12 (52.2) 3 (13.6) 4 (26.7)
ADL 6 (31.6) 9 (42.9) 11 (44.0) 6 (37.5) 6 (26.1) 8 (38.1) 12 (42.9) 8 (22.2) 10 (43.5) 7 (31.8) 6 (40.0)
Mobility 9 (47.4) 11 (52.4) 11 (44.0) 7 (43.8) 10 (43.5) 10 (47.6) 15 (53.6) 13 (36.1) 13 (56.5) 8 (36.4) 7 (46.7)
HRQOL 2 (10.5) 7 (33.3) 10 (40.0) 4 (25.0) 7 (30.4) 7 (33.3) 11 (39.3) 5 (13.9) 8 (34.8) 8 (36.4) 3 (20.0)
All COS 1 (5.3) 5 (23.8) 3 (12.0) 2 (12.5) 5 (21.7) 3 (14.3) 4 (14.3) 2 (5.6) 5 (21.7) 0 (0.0) 0 (0.0)
ADL – activities of daily living; COS – core outcome set; HRQOL – health-related quality of life; N – number of trial registrations
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Figure 1: Graph of uptake of core domain for the hip fracture core outcome set from 2004 to 2018 (where 10 or more registrations were recorded per 
year).
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Supplementary Table 1: Characteristics of included trials registered on ClinicalTrials.gov
Characteristic Number (%) of 
trials (N=311)
Trial Phase
1 7 (2)
2 22 (7)
3 42 (14)
4 61 (20)
5 23 (7)
Not stated 156 (50)
Study Type
Interventional 309 (99)
Reliability of Assessment Methods 1 (0.3)
Diagnostic Test Accuracy of Imaging Modality 1 (0.3)
Trial Design
RCT 269 (87)
Non-RCT 42 (14)
Intervention Type
Surgical 99 (32)
Perioperative General 84 (27)
Pre-operative 20 (6)
Intra-operative (non-surgical) 68 (22)
Rehabilitation 40 (13)
Trial duration
Mean duration (months; SD) 9.38 (17)
Not documented 11
Planned sample size
Mean sample size (SD) 195.5 (299)
Not documented 3 (1)
Trial status
Complete 133 (43)
Recruiting 62 (20)
Terminated 23 (7)
Not yet recruiting 12 (4)
Active, not recruiting 18 (6)
Withdrawn 10 (3)
Suspended 1 (0)
Enrolling by invitation 1 (1)
Unknown status 51 (16)
Participants with Cognitive Impairment recruited
Yes 138 (44)
No 170 (55)
Not stated 3 (1)
Funding Source
Research Council 18 (6)
Industry 48 (15)
Mixed (Research Council & Industry) 0 (0)
Not stated 245 (79)
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Principal continent of registration
Europe 133 (43)
Asia 75 (24)
North America 95 (31)
South America 3 (1)
Australasia 5 (2)
Africa 0 (0)
Antarctica 0 (0)
Year of Registration 
1997-2001 7 (2)
2002-2006 37 (12)
2007-2011 93 (30)
2012-2016 131 (42)
2017-2018 37 (12)
Not documented 6 (2)
RCT – randomised controlled trial; SD – standard deviation
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Supplementary Table 2: Country of origin for registered trial protocols
Country of Origin Frequency (%)
USA 82 (26.4)
China 25 (8.0)
Denmark 23 (7.4)
Israel 23 (7.4)
UK 20 (6.4)
Norway 19 (6.1)
France 18 (5.8)
Spain 14 (4.5)
Sweden 14 (4.5)
Canada 13 (4.2)
Switzerland 9 (2.9)
Netherlands 5 (1.6)
South Korea 5 (1.6)
Taiwan 5 (1.6)
Thailand 5 (1.6)
Australia 4 (1.3)
Turkey 4 (1.3)
Greece 3 (1.0)
Japan 3 (1.0)
Ireland 2 (0.6)
Finland 2 (0.6)
Italy 2 (0.6)
Brazil 2 (0.6)
Tunisia 2 (0.6)
Chile 1 (0.3)
Egypt 1 (0.3)
Germany 1 (0.3)
New Zealand 1 (0.3)
Portugal 1 (0.3)
Singapore 1 (0.3)
Syria 1 (0.3)
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Supplementary Figure 1: Flow-chart of identification of trial registrations from ClinicalTrial.gov 
database
All registrations in ClinicalTrials.gov on point of 
assessment
(N=278,399)
All registrations relating to hip fracture trials 
(N=355)
Non-potentially eligible registrations (N=278,044)
Not Eligible (with reasons)
(N=44)
 Recruitment of hip fracture and other 
patient groups (N=22)
 Pelvic fracture management (N=14)
 Fracture prevention interventions (N=8)
Eligible trial registrations
(N=311)
Trial ongoing, suspended or 
withdrawn
(N=104)
Trial completed or terminated
(N=156)
Trial of unknown status
(N=51)
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